NCT07840729
Evaluate the Safety and Tolerability of Multiple Doses of JMT206 Injection in Obese Participants
Free. We email you which fields changed when ClinicalTrials.gov updates this record.
Record History
All 2 versions: 2 with changes below.
- Notable Recruitment opened
- Site details revised
- Study First Submitted
- Notable: the plan changed
Endpoints
Primary
Arms and interventions
JMT206 injection dose 2 administered subcutaneously (SC) once a week
JMT206 injection dose 3 administered subcutaneously (SC) once a week
JMT206 injection dose 1 administered subcutaneously (SC) once a week. Semaglutide administered subcutaneously once a week, starts from lower dose and is gradually increased.
JMT206 injection dose 2 administered subcutaneously (SC) once a week. Semaglutide administered subcutaneously once a week, starts from lower dose and is gradually increased.
JMT206 injection dose 3 administered subcutaneously (SC) once a week. Semaglutide administered subcutaneously once a week, starts from lower dose and is gradually increased
Placebo administered subcutaneously (SC) once a week
Placebo administered subcutaneously (SC) once a week. Semaglutide administered subcutaneously once a week, starts from lower dose and is gradually increased.
JMT206 injection dose 1 administered subcutaneously (SC) once a week
Drugs: JMT206 injection, Placebo injection
Combination products: Semaglutide injection
Sites
1 site in 1 country
- Peking University People's HospitalBeijing, China